Baxter 261201:PEGylated Recombinant Factor VIII in Severe Hemophilia A

• Research type

  Research Study

• Full title

  A Phase 2/3, Multi-Center, Open Label Study of Efficacy, Safety, and Pharmacokinetics of PEGylated Recombinant Factor VIII (BAX 855) Administered for Prophylaxis and Treatment of Bleeding in Previously Treated Patients with Severe Hemophilia A

• IRAS ID

  119774

• Contact name

  Charles Hay

• Contact email

  Charles.hay@cmft.nhs.uk

• Sponsor organisation

  Baxter Innovations GmbH

• Eudract number

  2012-003599-38

• Clinicaltrials.gov Identifier

  NCT01736475

• REC name

  East Midlands - Nottingham 2 Research Ethics Committee

• REC reference

  13/EM/0084

• Date of REC Opinion

  22 Apr 2013

• REC opinion

  Further Information Favourable Opinion